Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-14
2011-06-14
Chong, Yong S (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S449000, C514S461000
Reexamination Certificate
active
07960433
ABSTRACT:
Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formulaor pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).
REFERENCES:
patent: 4170588 (1979-10-01), Hegenberg et al.
patent: 4639523 (1987-01-01), Nohara et al.
patent: 5206252 (1993-04-01), Butera et al.
patent: 5354763 (1994-10-01), Butera et al.
patent: 5397790 (1995-03-01), Butera et al.
patent: 5401753 (1995-03-01), Butera et al.
patent: 5403853 (1995-04-01), Butera et al.
patent: 5466712 (1995-11-01), Butera et al.
patent: 5506252 (1996-04-01), Butera et al.
patent: 5532245 (1996-07-01), Butera et al.
patent: 5840764 (1998-11-01), Quaqliato et al.
patent: 6297265 (2001-10-01), Widdowson et al.
patent: 6300325 (2001-10-01), Widdowson et al.
patent: 6376555 (2002-04-01), Butera et al.
patent: 6420396 (2002-07-01), Albers et al.
patent: 6878709 (2005-04-01), Taveras et al.
patent: 6903131 (2005-06-01), Taveas et al.
patent: 7132445 (2006-11-01), Taveas et al.
patent: 2002/0028238 (2002-03-01), Karim et al.
patent: 2003/0204085 (2003-10-01), Taveras et al.
patent: 2004/0186142 (2004-09-01), Taveras et al.
patent: 26 38 855 (1978-03-01), None
patent: 33 09 655 (1984-09-01), None
patent: 0 275 997 (1988-07-01), None
patent: 0 376 079 (1990-07-01), None
patent: 0 796 243 (1999-01-01), None
patent: 1 531 943 (1968-07-01), None
patent: 1186096 (1970-04-01), None
patent: WO 94/29277 (1994-12-01), None
patent: WO 95/14005 (1995-05-01), None
patent: WO 96/14300 (1996-05-01), None
patent: WO 96/15103 (1996-05-01), None
patent: WO 98/33763 (1998-08-01), None
patent: WO 00/20378 (2000-04-01), None
patent: WO 00/21927 (2000-04-01), None
patent: WO 00/35855 (2000-06-01), None
patent: WO 00/35864 (2000-06-01), None
patent: WO 00/73260 (2000-12-01), None
patent: WO 01/29000 (2001-04-01), None
patent: WO 01/64208 (2001-09-01), None
patent: WO 01/64691 (2001-09-01), None
patent: WO 01/68569 (2001-09-01), None
patent: WO 01/92202 (2001-12-01), None
patent: WO 02/057230 (2002-07-01), None
patent: WO 02/067919 (2002-09-01), None
patent: WO 02/076926 (2002-10-01), None
patent: WO 02/083624 (2002-10-01), None
patent: WO 03/080063 (2003-10-01), None
Chemical Abstract 66:18527 for Maahs, Guenther, et al., “Syntheses and derivatives of squaric acid,”Angewandte Chemie78(20):927-31 (1966) (which is attached to said abstract).
Chemical Abstract 87:134383 for Augustin, Manfred, et al., “Disubstitution in 2,3-dichloromaleimides”Zeitschrift FuerChemie 17(6):215-216 (1977) (which is attached to said abstract).
Chemical Abstract No. 87:151727 for Ehrhardt, Heinz, et al., “Amides and thioamides of squaric acid: syntheses and reactions,”Chemische Berichte110(7):2506-23 (1977) (which is attached to said abstract).
Chemical Abstract 104:129517 for Gruenefeld, Johann, et al., “Reactions of squaric acid with carbodiimides,”Archlv der Pharmazie318(12):1062-70 (1985) (which is attached to said abstract).
Chemical Abstract No. 122:160745 for Tillack, Annegret, et al., “Assymmetric catalysis. IV. Hydrosilylation of acetophenone with pyrroline-2,5-dione modified [Rh(COD)C1]2 catalyst,”Journal of Organometallic Chemistry482:85-91 (1994) (which is attached to said abstract).
Chemical Abstract No. 125:300482 for Chen, Yizhao, et al., “Reaction of dibutyl oxosquarate with aromatic primary amines,”Sichuan Daxue Xuebao, Ziran Kexueban33(2):182-186 (1996) (which is attached to said abstract).
Chemical Abstract No. 130:222994 for Chen, Yi-Zhao, et al., “Synthesis of asymmetric aryl-substituted amides of squaric acid and asymmetric isosquarylium amides,”Hechen Huaxue6(4):383-392 (1998) (which is attached to said abstract).
Butera, John A., et al., “Design and SAR of Novel Potassium Channel Openers Targeted for Urge Urinary Incontinence. 1.N-Cyanoguanidine Bioisosteres Possessing in Vivo Bladder Selectivity,”J. Med. Chem. 43:1187-1202 (2000).
Davis, Peter D., et al., “Inhibitors of protein kinase C 1. 2,3-Bisarylmaleimides,”J. Med. Chem. 35:177-184 (1992).
Hanaineh-Abdelnour, Leila, et al., “Some synthetic applications of 2,3-Dichloro-N-phenylmaleimide: A Novel Synthesis of 2-Phenylpyrrolo[3,4-b]quinoxaline-1,3-diones. I,”Tetrahedron55:11859-11870 (1999).
Neuse, Eberhard W., et al., “Poly(squaryl amides)”Polymer15:339-45 (1974).
Patent Abstracts of Japan, vol. 018, No. 361 (c-1222), Jul. 7, 1994 and JP 06 092915A, Apr. 5, 1994 abstract.
Zhou, Hai-Bing, et al., “Design, synthesis and structure of new chiral squaric acid monoaminoalcohols and diaminoalcohols and their use as catalysts in asymmetric reduction of ketones and diketones,”Tetrahedron57:9325-9333 (2001).
Glynn, P.C., Hall, H.I.P. Pulmonary Pharmacology & Therapeutics 2002, 15, 103-110.
Hay, D.W.P.; Sarau, H.M., Curr. Opin. Pharmacology 2001,1, 242-247.
Miller, D.D., In “Structure-Activity Relationship and Drug Design” Remington: The Science and Practice or Pharmacv, Nineteenth Edition vol. 1 (1995) Easton, PA: Mack Publishing Co. p. 425.
PCT International Search Report dated Jun. 24, 2003 for corresponding PCT Application No. PCT/US03/08287.
Biju Purakkattle J.
Billah Motasim
Bober Loretta A.
Chao Jianhua
Fine Jay S.
Chong Yong S
Jeannette Henry C.
Meade Eric A.
Russell Mark
Schering Corporation
LandOfFree
Treatment of chemokine mediated diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of chemokine mediated diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of chemokine mediated diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720525